Xencor, Inc.

Genentech, Inc.

Suzanne Schubbert

John R Desjarlais

Matthew J Bernett

Rajat Varma

Christine Bonzon

Juan Diaz

Rumana Rashid

Michael Hedvat

Christine Huang

Patrick Holder

Raphael Clynes

The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc fusion protein and an antigen binding domain Fc fusion proteins. In some instances, the antigen binding domain binds to CD8, NKG2A, or NKG2D.

Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains

The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen binding domains. The present invention also relates to nucleic acid molecules, expression vectors, host cells and methods for making such fusion proteins and the use of such fusion proteins in the treatment of cancer.

PD-1 targeted IL-15/IL-15Rα Fc fusion proteins with improved properties

Provided herein are dimeric IL-7-Fc fusion proteins that include Fc domains and one or more IL-7s. Also provided herein are variant IL-7s with modifications to reduce heterogeneity and/or reduced affinity/potency. Such variant IL-7s are useful, for example, in the subject dimeric IL-7-Fc fusion proteins. The dimeric IL-7-Fc fusion proteins can be used for applications where increased IL-7 activity is useful, for example, for increasing the proliferation of lymphocyte populations in mounting an anti-tumor response in a subject in need thereof.

IL-7-FC-fusion proteins

The present invention is directed to novel PD-1 targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R&#x3b1; Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein. In some embodiments, the PD-1 targeted IL-15/R&#x3b1;-Fc fusion proteins are administered to a patient to treat cancer. In some embodiments, the PD-1 targeted IL-15/R&#x3b1;-Fc fusion proteins are administered in combination with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab. In some embodiments, the PD-1 targeted IL-15/R&#x3b1;-Fc fusion proteins do not compete with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab for antigen binding.

PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof

The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R&#x3b1; Fc fusion protein and an antigen binding domain Fc fusion proteins. In some instances, the antigen binding domain binds to CD8, NKG2A, or NKG2D.

Growing community of inventors

Long Beach, CA, United States of America

Suzanne Schubbert